Spalax fibroblast-derived Anti-cancer agents

Inactive Publication Date: 2014-09-04
CARMEL HAIFA UNIV ECONOMIC
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is related to a method for identifying and producing an anti-cancer agent by using a conditioned cell culture medium of cells derived from Spalax or naked mole rat. The conditioned cell culture medium contains various active fractions that can kill or inhibit the growth of cancer cells but have no or little effect on normal cells. The invention also provides a pharmaceutical composition comprising the active agent and a carrier, excipient, or diluent for treatment of cancer or inhibition of cancer metastasis. The technical effects of the invention include the development of a new anti-cancer agent and the use of a novel approach in treating cancer.

Problems solved by technology

Notwithstanding steady progress in the understanding of this multifaceted disease, many cancers still are not treatable.
Laboratory mice and rats provided invaluable knowledge in biomedical research and pharmaceutics; however, these animals were subjected to inbreeding and artificial selection for the experiments' standardization purposes, which ultimately caused loss of stress tolerance and naturally selected features.
Hypoxia can result in a failure to maintain essential cellular functions and contributes to cardio- and cerebrovascular failure, pulmonary diseases and cancer, which together are the primary sources of morbidity in the western world.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Spalax fibroblast-derived Anti-cancer agents
  • Spalax fibroblast-derived Anti-cancer agents
  • Spalax fibroblast-derived Anti-cancer agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

Resistance of Spalax to Chemically-Induced Cancer

[0093]To assess experimentally if Spalax is resistant to chemically-induced carcinogenesis, we treated animals from different rodent species according to the following protocols:

[0094]DMBA / TPA Treatment:

[0095]Spalax and C57BL / 6 mice were treated with DMBA / TPA to induce skin carcinogenesis (Goerttler et al. 1982). Spalax animals developed severe skin lesions within ten days (FIG. 1A, upper middle panel). Histological examination of hematoxylin and eosin stained tissue sections demonstrated extensive skin necrosis involving the deep parts of the dermis, massive infiltration of the affected areas with neutrophil leukocytes, and ulcerated epidermis focally covered with fibrino-purulent exudates (FIG. 1A, lower middle panel). The subcutaneous skeletal muscle and bone tissues were not affected, and no tumor was identified. The wounds completely healed within 7-9 weeks, resulting in epidermal thickening (FIG. 1A, right panels), and no furthe...

example 2

Spalax Fibroblasts Suppress Growth of Cancer Cells In Vitro

[0099]To compare the effects of Spalax and mouse fibroblasts on growth of human epithelial cancer (Hep3B), we used a co-culture approach, where skin fibroblasts isolated from newborn rodents were cultured together with cancer cells on a shared surface (FIG. 4). The number of cancer cells co-cultured with mouse fibroblasts increased gradually, and on Day 7, Hep3B cells surrounded by mouse fibroblasts reached ˜80% confluence, similar to control (Hep3B only). In contrast, obvious inhibition of cancer cell growth was found when Hep3B cells were co-cultured with Spalax fibroblasts: foci of destroyed cancer cells were visible (FIG. 4). Prolonged co-cultivation up to 11 days resulted in further destruction of cancer cell colonies by Spalax fibroblasts and the spaces previously occupied by Hep3B cells were invaded by fibroblasts. Overgrown Hep3B colonies were found when co-cultured with mouse fibroblasts.

[0100]Since we compare a wil...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A conditioned cell culture medium of cells derived from Spalax or naked mole rat (Heterocephalus glaber) and methods for preparing it are provided. Pharmaceutical compositions comprising the conditioned cell culture medium and its use in the treatment of cancer as well as methods for identifying anti-cancer agents are also provided.

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS[0001]This application claims priority under 35 U.S.C. §119(e) from U.S. provisional patent application No. 61 / 751,051 filed on Jan. 10, 2013, which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention is in the field of cancer treatment and in particular to compositions comprising Spalax derived anti-cancer agents.[0004]2. Background Information[0005]Cancer is one of the leading causes of death in the world. Notwithstanding steady progress in the understanding of this multifaceted disease, many cancers still are not treatable. Laboratory mice and rats provided invaluable knowledge in biomedical research and pharmaceutics; however, these animals were subjected to inbreeding and artificial selection for the experiments' standardization purposes, which ultimately caused loss of stress tolerance and naturally selected features.[0006]Throughout the last fort...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/12C12N5/077
CPCC12N5/0656A61K35/33
Inventor AVIVI, AARONSHAMS, IMADMANOV, IRENA
Owner CARMEL HAIFA UNIV ECONOMIC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap